CAMP4 THERAPEUTICS CORPORATION (CAMP) - GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - CAMP4 THERAPEUTICS CORP

Explicit Guidance:

• Financial Runway: $124 million cash on hand (as of Q3) extends operations through the end of 2028, sufficient to cover the first half of 2028 data readout for the SYNGAP1 program.
• Clinical Data Timing: Initial Phase I/II data for the SYNGAP1 program (CMP-002) expected in the first half of 2028; no interim safety or pharmacokinetics readouts planned prior to this window.
• Regulatory Milestones: Anticipates approaching the FDA for discussions similar to those completed in Australia, Argentina, the UK, and via the EMA.
• Revenue/Commercial: No specific quantitative revenue or pricing guidance provided; CEO characterizes peak sales potential as "massive," comparing unmet need severity to spinal muscular atrophy and cystic fibrosis.

Business-Segment Outlook:

• SYNGAP1 Program: First-in-class disease-modifying antisense approach targeting CNS haploinsufficiency; clinical dosing of first patients expected by end of current year (2024/2025 context).
• SHANK3 Program: New program for Phelan-McDermid syndrome announced; expected to follow a "rinse, wash, repeat" success trajectory relative to SYNGAP1, targeting 45,000 U.S. patients.
• Pipeline Expansion: Two undisclosed CNS programs active; GSK partnership covers two additional non-CNS indications (one large CNS, one kidney disease) identified by GSK.
• Platform Scalability: Platform is broadly applicable to any tissue where gene upregulation is required; biological mechanism limits upregulation to approximately 2-fold, mitigating overexpression risks.

Market and Competitive Outlook:

• Competitive Landscape: Described as "sparse"; Camp 4 is "furthest along" in clinical development. Advantage derived from transcriptional targeting which produces all six SYNGAP1 isoforms naturally, a feature competitors using gene therapy or splice-switching cannot replicate.
• Market Size: SYNGAP1 patient population estimated at 10,000+ in the U.S. (likely underdiagnosed); SHANK3 estimated at 45,000 in the U.S.
• Diagnostic Trends: Diagnostic timeline for rare diseases has compressed from a "10-year odyssey" to one year due to improved awareness and genetic screening; this is expected to expand the treatable patient pool over time.
• Pricing Strategy: Anticipates "premium pricing" due to unmet need, though no specific price points are disclosed.

Macro / Industry Outlook:

• Regulatory Environment: Management notes a "really positive" trend at the FDA regarding rare disease approaches, specifically encouraging the use of control arms to support potential accelerated approval pathways.
• Trial Design Philosophy: Willing to define success with regulatory agencies based on signal-seeking data, leveraging natural history data (1,400+ years) and multiple control systems (external natural history, internal baseline, randomized control arm) to facilitate future pivotal discussions.

Strategic Initiatives:

• Clinical Trial Execution: Phase I/II design is a global multiple ascending dose study (3-to-1 randomization) with three cohorts, allowing patients to receive up to three doses over three months followed by a six-month follow-up.
• Geographic Expansion: Regulatory clearance secured in four regions (Australia, Argentina, UK, EMA); currently initiating FDA discussions.
• Business Development: Active pursuit of "asset-based" discovery deals; GSK partnership structure involves Camp 4 identifying regulatory RNAs/creating ASOs, then handing off to GSK for clinical/commercial development in exchange for milestones and royalties.
• Technology: Utilizing Gen 2 chemistry (Spinraza proven) for intrathecal delivery to ensure brain/hypothalamic/cortical distribution.

Risks and Headwinds to Outlook:

• Clinical Success Probability: Current status is "signal-seeking" with no established optimal biological dose; success in Phase I/II is a prerequisite for unlocking value in the platform and other programs.
• Regulatory Pathway: No prior disease-modifying therapies exist for SYNGAP1, creating uncertainty regarding the specific regulatory path and endpoints required for approval.
• Competition: While currently leading, management expects "more competition is coming" from other companies, though they believe their transcriptional mechanism offers a rational advantage.
• Data Timing: Management explicitly states they will not release data earlier than the first half of 2028 to maintain credibility ("cake will be baked and ready to be eaten"), limiting interim information flow.

Management Tone on the Future:

• Confidence Level: High confidence in the platform's biological mechanism ("never get above a two-fold increase" prevents toxicity) and the potential for the SYNGAP1 program to validate the entire portfolio.
• Valuation View: Management describes the current stock price as "deeply undervalued" relative to the potential if the SYNGAP1 data is positive, noting that probability of success should "massively" increase for subsequent programs once the platform is clinically validated.
• Operational Stance: "Heads down" execution strategy; intent to keep cash spending "tight" while focusing entirely on hitting the first half 2028 milestone.